Octreotide is a lab-made version of somatostatin, the body’s own “off switch” hormone, built to last longer. This guide covers its structure, how it works, what FDA approved it for, the key trials and what its labels warn about. Sources were checked on November 17, 2026.
Quick answer: Octreotide is a prescription peptide drug that copies the action of somatostatin. It lowers growth hormone and blocks the release of several gut hormones. FDA approved it for acromegaly and for symptoms of two kinds of hormone-releasing tumors.
Vitrapep does not sell octreotide; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is octreotide?
Octreotide is a synthetic peptide. The Sandostatin label calls it a “cyclic octapeptide,” meaning a ring-shaped chain of eight units (Sandostatin label). Its chemical name lists phenylalanine, cysteine, phenylalanine, tryptophan, lysine, threonine and a second cysteine. Two of those units are D-amino acids, the mirror-image form. The chain ends in an amino alcohol group instead of a standard acid end. A disulfide bond joins the cysteines at positions 2 and 7, which closes the ring.
Octreotide belongs to the somatostatin analog class. The Octreoscan label describes octreotide as “a long-acting analog of the human hormone, somatostatin” (Octreoscan label). PubChem lists its formula as C49H66N10O10S2 and its molecular weight as 1019.2 g/mol (PubChem CID 448601). For background on hormone peptides, see our overview of peptide hormones.
FDA first approved octreotide on October 21, 1988, as Sandostatin. Drugs@FDA lists that approval under NDA 019667 as a new molecular entity with priority review (Drugs@FDA). Later brands include Sandostatin LAR Depot and Mycapssa, which FDA approved on June 26, 2020 (Drugs@FDA).
Octreotide: key facts
| Fact | Detail |
|---|---|
| Structure | Cyclic peptide of eight units, closed by a disulfide bond |
| Class | Somatostatin analog |
| Molecular formula | C49H66N10O10S2 (PubChem) |
| Molecular weight | 1019.2 g/mol (PubChem) |
| First FDA approval | October 21, 1988 (Sandostatin, NDA 019667) |
| Approved brands | Sandostatin, Sandostatin LAR Depot, Mycapssa |
How does octreotide work?
Somatostatin is a natural hormone that slows the release of other hormones. Octreotide copies that action. The label states that octreotide “exerts pharmacologic actions similar to the natural hormone, somatostatin” (Sandostatin label).
According to the label, octreotide is an even stronger brake than somatostatin on growth hormone, glucagon and insulin. It also blunts the luteinizing hormone response to gonadotropin-releasing hormone. It reduces blood flow to the gut organs. And it blocks the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin and pancreatic polypeptide.
What is octreotide approved for?
Each brand has its own label. In plain terms, the indications sections say:
- Sandostatin (1988): approved to reduce blood levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in acromegaly. This applies when surgery, pituitary irradiation and bromocriptine have not worked well enough or cannot be used. It is also approved for severe diarrhea and flushing linked to metastatic carcinoid tumors. And it is approved for the profuse watery diarrhea of VIP-secreting tumors (VIPomas).
- Sandostatin LAR Depot: approved for long-term treatment of the same three conditions, in patients for whom Sandostatin has already proved effective and tolerated (Sandostatin LAR Depot label).
- Mycapssa (2020): approved for long-term maintenance treatment in acromegaly patients who have responded to and tolerated octreotide or lanreotide (Mycapssa label).
The labels also set limits. The Sandostatin label says improvement in signs and symptoms, or in tumor size or growth, was not shown in its trials. The Sandostatin LAR Depot label says the effect on tumor size, growth and spread in carcinoid syndrome and VIPomas “has not been determined.”
What did the key trials of octreotide show?
Two human trials stand out. One supported a newer brand. The other tested a question the US labels leave open.
CHIASMA OPTIMAL (acromegaly). This Phase 3 trial was double-blind and placebo-controlled (NCT03252353). It randomized 56 adults whose acromegaly was already controlled on somatostatin analog therapy. They switched to the octreotide product later sold as Mycapssa, or to placebo, for 36 weeks. The primary endpoint was keeping IGF-1 at or below the upper limit of normal. At the end, 58.2% of the octreotide group kept that control, versus 19.4% on placebo (P = .008) (Samson et al., 2020).
PROMID (midgut neuroendocrine tumors). This double-blind trial randomized treatment-naive patients with metastatic midgut tumors to octreotide or placebo. The primary endpoint was time to tumor progression. At the planned interim analysis of 85 patients, the median was 14.3 months with octreotide and 6 months with placebo (hazard ratio 0.34) (Rinke et al., 2009). Slowing tumor growth is not a US labeled indication for octreotide.
What side effects does the octreotide label list?
No octreotide label we read carries a boxed warning. The most common adverse reactions differ by brand and by condition.
- Sandostatin, acromegaly: gallbladder abnormalities, slow heart rate (sinus bradycardia), diarrhea, loose stools, nausea and abdominal discomfort. High blood sugar and underactive thyroid also top 10%.
- Sandostatin LAR Depot: in acromegaly, diarrhea, gallstones, abdominal pain and gas, each in at least 20%. In carcinoid syndrome, back pain, fatigue, headache, abdominal pain, nausea and dizziness.
- Mycapssa: nausea, diarrhea, headache, joint pain, weakness, heavy sweating and raised blood sugar, among others above 10%.
In acromegaly patients, the Sandostatin label reports sinus bradycardia in 25%. Diarrhea, loose stools, nausea and abdominal discomfort were each seen in 34% to 61%. The warnings sections also cover thyroid and heart rhythm effects, poor fat absorption and vitamin B12 changes.
What is the regulatory status of octreotide, and is it used in research?
Octreotide is a prescription drug. Drugs@FDA lists Sandostatin and Mycapssa with a marketing status of “Prescription.” FDA’s Drug Safety Communications page, current as of November 9, 2026, lists no communication about octreotide from 2020 onward (FDA). WADA’s 2026 Prohibited List does not name octreotide. Our guide to peptides on the 2026 WADA list explains the sections.
Octreotide also anchors imaging research. FDA approved Octreoscan on June 2, 1994 (Drugs@FDA). Its label says its active part, pentetreotide, “is a DTPA conjugate of octreotide.” It is used to locate neuroendocrine tumors that carry somatostatin receptors. Human trials like PROMID also test octreotide beyond its labeled uses.
Frequently asked questions about octreotide
Is octreotide a peptide?
Yes. The Sandostatin label calls it a cyclic octapeptide, a ring of eight amino acid units. Our page on types of peptides explains cyclic peptides.
Is octreotide the same as somatostatin?
No. It is a synthetic analog. The label says it acts like somatostatin but is a more potent inhibitor of growth hormone, glucagon and insulin.
What is octreotide approved for?
Acromegaly, plus severe diarrhea and flushing from metastatic carcinoid tumors and watery diarrhea from VIPomas. Mycapssa is approved only for maintenance treatment in acromegaly.
Does octreotide have a boxed warning?
No. None of the three labels we read carries one.
Is octreotide banned in sport?
WADA’s 2026 Prohibited List does not name it. Athletes should check with their anti-doping organization.
What to know now
- What it is: a cyclic eight-unit peptide that mimics somatostatin; 1019.2 g/mol.
- First approval: Sandostatin, October 21, 1988; Mycapssa followed in 2020.
- Approved for: acromegaly, and symptoms of metastatic carcinoid tumors and VIPomas.
- Key data: 58.2% versus 19.4% kept acromegaly control in CHIASMA OPTIMAL.
- Safety: no boxed warning; gallbladder problems and digestive upset are common.
- Status: prescription only; not named on WADA’s 2026 list.
What we’re watching
FDA’s decision on CAM2029, a new octreotide product for acromegaly. Camurus says FDA set a target action date of December 18, 2026 (Camurus, 2026). An earlier complete response letter, dated June 10, 2026, related to a third-party manufacturer inspection. The same product is in SORENTO, a Phase 3 trial in 332 people with gastroenteropancreatic neuroendocrine tumors. Its primary completion is estimated for November 2026 (NCT05050942). We also track label updates on DailyMed.